ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome

Purpose: Cisplatin resistance is a major obstacle in the treatment of ovarian carcinoma. ABCC2 is commonly localized in apical cell membranes and could confer cisplatin resistance. Here, we show that ABCC2 can be localized in the cytoplasmic membrane as well as in the nuclear membrane of various human tissues including ovarian carcinoma cells. Experimental Design: For the subcellular detection of ABCC2, immunohistochemistry was done using 41 Federation Internationale des Gynaecologistes et Obstetristes stage III ovarian carcinoma specimens prepared before treatment with cisplatin-based schemes and 35 specimens from the same group after chemotherapy. Furthermore, 11 ovarian carcinoma cell lines as well as tissue microarrays consisting of various human tissues were analyzed. Results: Nuclear membranous localization of ABCC2 was associated with response to first-line chemotherapy at primary (P = 0.0013) and secondary surgery (P = 0.0060). Cases with relapse showed higher nuclear membrane expression at primary (P = 0.0003) and secondary surgery (P = 0.0024). Kaplan-Meier analyses showed that weak nuclear membrane ABCC2 expression before treatment was associated with significantly longer overall (P = 0.04) and progression-free survival (P = 0.001); following chemotherapy, it correlated with significantly longer progression-free survival (P = 0.038). Tissue microarrays confirmed nuclear membranous localization of ABCC2, in particular, in poorly differentiated cells. In ovarian carcinoma cells, it correlated with resistance against cisplatin, whereas localization in the cytoplasmic membrane did not. Conclusions: ABCC2 confers resistance to cisplatin of ovarian carcinoma in cell culture systems and in clinics when expressed in the nuclear membrane. Thus, ABCC2 localization can predict platinum therapy outcome. Furthermore, expression of ABCC2 in nuclear membranes in human tissues is specific for poorly differentiated cells including stem cells.

[1]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[2]  M. Shah,et al.  Targeting the cell cycle: a new approach to cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[4]  D. Keppler,et al.  Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia. , 2001, Gastroenterology.

[5]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[6]  M. Kool,et al.  Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  C. Denkert,et al.  Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance , 2005, Breast Cancer Research.

[8]  Karl Kuchler,et al.  ABC proteins : from bacteria to man , 2003 .

[9]  K. Kohno,et al.  A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. , 1996, Cancer research.

[10]  D. Schadendorf,et al.  Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. , 2003, The Journal of investigative dermatology.

[11]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[12]  H. Lage.  ABC-transporters: implications on drug resistance from microorganisms to human cancers. , 2003, International journal of antimicrobial agents.

[13]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[14]  N. Kinukawa,et al.  ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[16]  H. Lage,et al.  Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cells , 2005, International journal of cancer.

[17]  Costan,et al.  Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. , 1996, Cancer research.

[18]  B. Rost,et al.  Finding nuclear localization signals , 2000, EMBO reports.

[19]  A. Donnenberg,et al.  Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis , 2005, Journal of clinical pharmacology.

[20]  K. Kohno,et al.  Mutations in the Canalicular Multispecific Organic Anion Transporter (cMOAT) Gene, a Novel ABC Transporter, in Patients with Hyperbilirubinemia II/Dubin-Johnson Syndrome , 1998 .

[21]  H. Lage,et al.  Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  B. Stewart,et al.  World Cancer Report , 2003 .

[23]  F. Akiyama,et al.  Toward the development of a universal grading system for ovarian epithelial carcinoma , 1998, Cancer.

[24]  C. Denkert,et al.  Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. , 2006, Cancer letters.

[25]  Jörg König,et al.  Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma , 2005, International journal of cancer.

[26]  H. Lage,et al.  RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. , 2004, Gynecologic oncology.

[27]  H. Lage,et al.  RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. , 2006, Biochemical and biophysical research communications.

[28]  G. Sandusky,et al.  Expression of multidrug resistance‐associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays , 2002, Histopathology.

[29]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.